PADRE universal T-helper epitope (PADRE)

PADRE (Pan-DR Epitope) universal T-helper epitope is a synthetic peptide designed to bind with high affinity to a broad range of human HLA-DR molecules (MHC class II), as well as murine I-Ab, enabling universal stimulation of CD4+ T helper cells regardless of MHC variant in the patient population[1][2][4]. PADRE is not itself a receptor, enzyme, transporter, or a traditional molecular therapeutic target; rather, it is used as an immunological adjuvant or functional motif in vaccine and immunotherapy design to enhance T-cell help, which is especially important for enabling strong, antigen-specific CD8+ cytotoxic T cell responses and antibody production to epitopes that are otherwise weakly immunogenic[1][2][4]. The PADRE peptide is often conjugated or co-administered with antigens to optimize vaccine-induced immunity and has been demonstrated in preclinical and clinical studies to facilitate robust immune responses, particularly in the context of cancer immunotherapy and infectious disease vaccines[1][2][4]. The name "PADRE" stands for "Pan-DR Epitope" and is not the name of a gene or protein native to any organism[1][2]. PADRE is not a drug target in the conventional sense, but rather a widely used immunological tool/epitope to provide universal T-helper signals in vaccines and immunotherapies. If looking for receptors or molecular targets, this is not a conventional entry—hence, the entry is marked as "is_incorrect: true"[1][2][4].

Other names

PADREPan-DR epitopePan-DR-binding epitopePADRE peptide

Acts as a universal CD4+ T-helper epitope that binds broadly to human HLA-DR (MHC class II) molecules, providing T-helper signals to facilitate antigen-specific CD8+ T cell and antibody responses[1][2][4].